Secreted UBE3A Vector for Angelman Syndrome Brain Distribution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Angelman syndrome, primarily focusing on palliative care, lack a therapeutic solution that effectively supplements UBE3A protein throughout the brain to address the underlying neuronal deficiencies, as existing gene therapy approaches like rAAV vectors face challenges in transducing a majority of UBE3A-deficient neurons.
Innovation Solution
A UBE3A vector is developed, incorporating a transcription initiation sequence, a UBE construct with a secretion sequence, and a recombinant adeno-associated virus serotype 2-based plasmid, which is administered intrahippocampally or intraventricularly to provide a therapeutically effective amount of UBE3A protein, potentially using a secreted form to enhance distribution within the brain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If rAAV vectors are used for gene therapy, then UBE3A protein can be delivered to neurons, but the ability to transduce a majority of UBE3A-deficient neurons is limited
Solution Approach 1:
The patent uses a secreted form of UBE3A protein as an intermediary that can be delivered via rAAV vectors and then distributed throughout the brain through natural secretory pathways. This intermediary approach allows the protein to reach areas that direct viral transduction cannot efficiently access, thereby improving overall protein distribution while maintaining reliable initial delivery through the vector.
Solution Approach 2:
The invention transitions from intracellular-only UBE3A expression to extracellular secretion, adding a new dimension of distribution. By engineering the UBE3A protein to be secreted, it can travel through the extracellular space and reach neurons that were not transduced by the viral vector, effectively expanding the therapeutic reach beyond the limitations of viral transduction efficiency.
2Object-affected harmful factors
If palliative care treatments are used, then symptom management is provided, but the underlying neuronal deficiencies are not addressed
Solution Approach 1:
The patent extracts and addresses the root cause of Angelman syndrome by delivering functional UBE3A protein directly to the brain, rather than merely treating symptoms. This extraction of the underlying deficiency and its direct correction transforms the approach from palliative symptom management to curative therapy that targets the fundamental neuronal deficiency.
Solution Approach 2:
The gene therapy approach performs preliminary action by establishing functional UBE3A expression before severe neurological damage occurs. By introducing the therapeutic mechanism early, the treatment can prevent or reverse neuronal deficiencies before they lead to irreversible damage, thereby achieving both symptom management and correction of underlying defects.
3Reliability
If UBE3A protein is supplemented locally, then synaptic plasticity deficits can be rescued, but broader distribution throughout the brain is limited
Solution Approach 1:
The secreted UBE3A protein acts as an intermediary that can diffuse from the site of expression to surrounding brain regions. This intermediary form allows the protein to travel beyond the immediate area of viral transduction and reach distant neurons, thereby expanding the distribution area while maintaining the therapeutic effect of synaptic plasticity rescue.
Solution Approach 2:
By engineering UBE3A for secretion, the invention adds extracellular distribution as a new dimension to protein delivery. This allows the protein to move through the extracellular space and reach areas that would not be accessible through direct cellular transduction alone, effectively expanding the therapeutic area without compromising synaptic plasticity benefits.
Data Source
AI summary
A novel vector, composition and method of treating a UBE3A deficiency disease is presented. A novel UBE3A vector construct was generated with an additional secretion sequence to allow the secretion from cells. This secreted only E6AP protein maintains its presence outside the cell and is capable of diffusing to greater distances to cover more of the brain and rescue disease pathology.